Treatment of Primary Plasma Cell Leukaemia With Carfilzomib and Lenalidomide-Based Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
Lancet Oncol 2023 Sep 14;[EPub Ahead of Print], NWCJ van de Donk, MC Minnema, B van der Holt, F Schjesvold, KL Wu, A Broijl, WWH Roeloffzen, A Gadisseur, G Pietrantuono, L Pour, VHJ van der Velden, T Lund, M Offidani, M Grasso, L Giaccone, W Razawy, P Tacchetti, K Mancuso, T Silkjaer, J Caers, S Zweegman, R Hájek, R Benjamin, AJ Vangsted, M Boccadoro, F Gay, P Sonneveld, P MustoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.